(UPDATED) Muddy conclusions from the GUIDE-HF trial hint that pulmonary artery pressure monitoring with the CardioMEMS device (Abbott) may help prevent heart failure (HF) hospitalizations in a broader ...
TEL AVIV, Israel--(BUSINESS WIRE)--Vectorious Medical Technologies Ltd., today announced that it has enrolled the first six patients in the VECTOR-HF II Study, which will evaluate the V-LAP System’s ...
ORLANDO, Fla. — Patients who underwent an ambulatory hemodynamic sensor implant had decreased risk for mortality and HF hospitalization compared with a control group, according to data presented at ...
Endotronix presented positive six-month results from its PROACTIVE-HF pivotal trial of the investigational Cordella Pulmonary Artery (PA) Sensor on March 5. The trial, in New York Heart Association ...
Please provide your email address to receive an email when new articles are posted on . Abbott announced its sensor providing hemodynamic-guided management of patients with HF has received an expanded ...
The trial met primary safety and efficacy endpoints, demonstrating a markedly low rate of heart failure hospitalizations for NYHA class III HF patients. The results support the company's pre-market ...
June 2, 2010 (Berlin, Germany)— Patients with advanced heart failure whose medications were adjusted according to readings from a tiny implanted pulmonary-artery (PA)-pressure sensor--a kind of ...
GEELONG, Australia—BAE Systems is supplying a high-frequency (HF) radio sensor to the U.S. government using technology originally developed for Australia’s Jindalee over-the-horizon radars. The U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback